Edition:
India

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.22USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,819
52-wk High
$4.25
52-wk Low
$0.78

Summary

Name Age Since Current Position

Carolyn Egbert

2016 Independent Chairman of the Board

Michael Ward

2017 President, Chief Executive Officer, Director

Jeffrey Whitnell

58 2017 Interim Chief Financial Officer

Richard Sachse

2014 Senior Vice President, Chief Scientific Officer, Chief Medical Officer

Jude Dinges

2013 Chief Commercial Officer, Senior Vice President

Eckhard Gunther

2017 Vice President - Alliance Management

Michael Teifel

2017 Vice President - Non-Clinical Sciences

John Sharkey

60 Business Development Consultant

Philip Theodore

64 2017 Corporate Secretary

David Dodd

65 2017 Director

M. Marcel Aubut

1996 Independent Director

Michael Cardiff

2016 Independent Director

Jose Dorais

2006 Independent Director

Juergen Ernst

78 2014 Independent Director

Gerard Limoges

75 2004 Independent Director

Biographies

Name Description

Carolyn Egbert

Ms. Carolyn Egbert is Independent Chairman of the Board of the Company. She has served as a director on our Board since August 2012 and as Chair of our Board since May 2016. After enjoying the private practice of law as a defense litigator in Michigan and Washington, D.C., she joined Solvay America, Inc. (“Solvay”) (a chemical and pharmaceutical company) in Houston, Texas. Over the course of a twenty-year career with Solvay, she held the positions of Vice President, Human Resources, President of Solvay Management Services, Global Head of Human Resources and Senior Executive Vice President of Global Ethics and Compliance. During her tenure with Solvay, she served as a director on the Board of Directors of seven subsidiary companies and as Chair of one subsidiary board. After retiring in 2010, she established a consulting business providing expertise in corporate governance, ethics and compliance, organizational development, executive compensation and strategic human resources. She holds a Bachelor of Sciences degree in Biological Sciences from George Washington University, Washington D.C. and a Juris Doctor degree from Seattle University, Seattle, Washington. She also was a Ph.D. candidate in Pharmacology at both Georgetown University Medical School at Washington, D.C. and Northwestern University Medical School at Chicago, Illinois. She remains an active member of both the Michigan State Bar and the District of Columbia Bar, Washington, D.C.

Michael Ward

Mr. Michael Ward is President, Chief Executive Officer, Director of the Company. He has over 30 years of executive and legal experience in the health care, pharmaceutical and technology industries. Most recently, Mr. Ward served as chief compliance and legal officer and corporate secretary for Sagent Pharmaceuticals, a global specialty generic pharmaceutical company, and led its sale to Nichi-Iko Pharmaceutical Co. Ltd. for $736-million. Mr. Ward has served as strategic adviser to Benevolent Capital Partners for the last five years and is currently a partner with Outside GC LLC. Prior to Sagent Pharmaceuticals, Mr. Ward was vice-president, assistant general counsel of global compliance, ethics and litigation, and chief privacy officer at CDK Global. Mr. Ward has served in several executive roles and was responsible for business development, compliance, legal and operational matters in the health care, pharmaceutical and technology industries during his career. Mr. Ward graduated from Albion College and Case Western Reserve University law school.

Jeffrey Whitnell

Mr. Jeffrey A. Whitnell is Interim Chief Financial Officer of the company. He He is an accomplished financial executive with a professional career spanning approximately 40 years in both large and small company environments working for various organizations in the life sciences and biopharmaceutical sectors. Mr. Whitnell brings extensive background in capital markets and corporate finance transactions. Most recently, he served as Vice-President, Finance & Controller of Lifewatch Services, Inc., a publicly traded medical device company servicing the cardiac monitoring market that was acquired by BioTelemetry, Inc. in July 2017. From April 2010 to March 2015, Mr. Whitnell served as Chief Financial Officer and Controller of Reliefband Medical Technologies, a private equity-backed medical device company, and from June 2004 to June 2009 Whitnell served as CFO of Akorn, Inc., a then publicly traded specialty pharma company that was recently acquired by Fresenius Kabi. Prior to that, Mr. Whitnell held multiple senior finance positions with various companies, including Ovation Pharmaceuticals, Medichem Life Sciences, Akzo Nobel and Motorola. He commenced his professional career as a staff auditor with Arthur Andersen & Co. Mr. Whitnell has a Bachelor's of Science degree in Accountancy from the University of Illinois and a Master's in Business Administration from The University of Chicago Booth School of Business.

Richard Sachse

Dr. Richard Sachse, M.D. Ph.D. is Senior Vice President, Chief Scientific Officer, Chief Medical Officer of Aeterna Zentaris Inc. He holds a degree in medicine from the Friedrich-Alexander-University Erlangen, in Germany, and a board certification in Clinical Pharmacology. With more than 20 years experience as a physician and scientist, he has extensive expertise in a variety of different therapeutic areas, including endocrinology and oncology. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic, as well as in the design and implementation of clinical pharmacology programs, including all required profiling studies and activities, enabling successful registration of products at the international level. From 1996 to 2000, he was International Project Leader at the Bayer AG Institute for Clinical Pharmacology, and Principal Investigator at the Bayer Clinical Pharmacology Unit, implementing innovative exploratory development tools, including biomarkers to demonstrate early Proof of Concept. From 2001 to 2006, Dr. Sachse held a variety of different management positions within early and late phase clinical development programs, including responsibilities for completed Phase 3 programs leading to successful NDA/MAA submissions. In 2007, after a merger, he became Senior Director, Head of Experimental Medicine, at UCB in Belgium, where he managed the implementation of novel biomarkers in clinical development to provide data supporting identification of appropriate target indication and target population. In 2010, Dr. Sachse became Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Jude Dinges

Mr. Jude Dinges is Chief Commercial Officer, Senior Vice President of Aeterna Zentaris Inc. He began his career nearly 30 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, sales, management, marketing, and market development. While at Merck, Mr. Dinges won multiple awards, including the President's Achievement Award in 2001, awarded to one of 32 Business Directors each year. He received the Change Agent Award for his market development prelaunch business planning and contributions to sales force execution, while launching the blockbuster brands Cozaar®, Fosamax®, Singulair®, Maxalt®, Vioxx®, and Vytorin®. He was recognized with a Career Achievement Award for his consistent top performance as a Senior/ Executive Business Director. Mr. Dinges joined Novartis Pharmaceuticals in 2006 and led his region to top performance in the launch of Tekturna® while balancing a broad antihypertensive portfolio across several Novartis divisions. His region also led the nation in market share for Exelon® and Exelon Patch®. In 2008, Mr. Dinges became the Respiratory & Infectious Disease Specialty Medicines Director. In 2009, Mr. Dinges joined Amgen Inc. as Executive Director of Region Sales, Bone Health Business Unit. Mr. Dinges led his region team to a highly successful launch of monoclonal antibody, Prolia®, across southeastern United States and Puerto Rico.

Eckhard Gunther

Mr. Eckhard G. Gunther Ph.D., is Vice President - Alliance Management of the company. He holds a degree in organic chemistry from the Martin-Luther University of Halle-Wittenberg, in Germany. With more than 25 years in the pharmaceutical industry, he has gained extensive experience in research coordination, project management, intellectual properties and business development. Dr. Guenther started his industrial career in 1985 at Fahlberg-List Magdeburg before joining ASTA Medica AG in Frankfurt in 1990 where he held various management positions, including head of Research Coordination and head of Medicinal Chemistry Oncology. After the foundation of Aeterna Zentaris in 2002, he was appointed Vice President of Drug Discovery and Preclinical Research. In 2008 he was promoted to Vice President Alliance Management & Intellectual Property and later on, to Vice President of Business Development. Dr. Guenther has been responsible for the initiation and execution of several R&D and licensing deals for Aeterna Zentaris with midsize and large international pharmaceutical companies, like Schering Pharma, Solvay, Yakult Honsha, Hikma Pharmaceuticals and Sinopharm A-Think.

Michael Teifel

Dr. Michael Teifel is Vice President - Non-Clinical Sciences of the Company. He joined the German subsidiary, which is based in Frankfurt, in 2004, where he has been involved in a number of roles focused on the design and implementation of nonclinical development programs for small molecule drugs, targeted therapies and biologics. He serves as one of the executive officers. Prior to joining us, Dr. Teifel co-founded Munich Biotech AG, which developed anti-tumor diagnostics and therapeutics, from 1998 through August 2004. Prior to founding Munich Biotech AG, Dr. Teifel was employed by Boehringer Mannheim GmbH/Roche Diagnostics GmbH where his focus was on gene therapy. He received his diploma in biology from the Technical University Darmstadt in 1992 and his doctorate from the same institution in 1996.

John Sharkey

Dr. John W. Sharkey, Ph.D. is Business Development of Consultant of the company. He holds a degree in electroanalytical chemistry from the State University of New York at Buffalo. With 30 years of experience in the pharmaceutical and medical device industry, he has extensive experience in pharmaceutical and clinical development, manufacturing, business development and operations. Dr. Sharkey started his pharmaceutical career in the pharmaceutical development group at Sandoz Pharmaceuticals, eventually being named the Head of Alternative Drug Delivery R&D prior to the merger with Ciba-Geigy to form Novartis. In 1996 Dr. Sharkey transferred to business development and held several positions of increasing responsibility, eventually being named VP of Business Development for Novartis Ophthalmics. In 2003 he joined Ophthalmic International as President and Head of Operations and in 2007 he joined Sciele Pharmaceuticals as VP of Business Development. Following Shionogi Pharma’s acquisition of Sciele in 2009, Dr Sharkey was named EVP of Business Development and Alliance Management for Shionogi Pharmaceuticals where he led the efforts to establish a global BD&L team for Shionogi Pharma. In 2010 Dr. Sharkey started Cógas Consulting, a boutique consultancy providing pharmaceutical development and business development services to small and mid-size pharma and medical device companies. Dr. Sharkey has been the lead, or a critical contributor, to several notable partnering transactions over the years including Novartis’ ex-US license with Genentech for Lucentis®, the transactions with Celgene and Elan for Focalin® as well as Shionogi’s global license for Osphena®. He has also assisted several companies in their financing activities over the years. In June of 2014 he was retained by Aeterna Zentaris to provide business development services on a consultancy basis.

Philip Theodore

Mr. Philip Allen Theodore is Corporate Secretary of Aeterna Zentaris Inc. He is a graduate of the University of Cincinnati College of Law, and holds a B.A. (Political Science) from the University of Tennessee at Chattanooga. Before joining Aeterna Zentaris, Philip Theodore served as Vice President, General Counsel and Corporate Secretary of Zep Inc., a leading global supplier of consumable chemical packaged goods. Prior to joining Zep Inc., he served as Vice President of Corporate Development, Compliance and Legal for BioReliance, Inc. from September 2008 to April 2009; as Senior Vice President and General Counsel of John H. Harland Company from September 2006 to September 2007; and as Vice President, General Counsel and Corporate Secretary of Serologicals Corporation from 2004 through August 2006. Mr. Theodore also served as a partner in the corporate practice of King & Spalding, LLP, an Atlanta-based law firm, from 1986 through 2003.

David Dodd

Mr. David A. Dodd is Director of Aeterna Zentaris Inc. Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. Prior to joining Aeterna Zentaris, Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc. During his six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of the company increased from $85 million in June 2000 to an all-cash sale to Millipore Corporation in July 2006 for $1.5 billion. He also was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories. Mr. Dodd holds a Master degree from Georgia State University, and completed the Harvard Business School Advanced Management Program.

M. Marcel Aubut

Mr. M. Marcel Aubut is Independent Director of AEterna Zentaris Inc. Mr. Aubut is a partner and Vice-Chairmain of the Board of BCF LLP, a law firm. The countless companies and boards with which Marcel Aubut has been involved over the years demonstrate his versatility and, above all, his vast experience in the world of business. These include, among others, Atomic Energy of Canada, Olymel L.P. (Olybro), Boralex Power Income Fund, Triton Electronik, Whole Foods Market Canada, Hydro-Québec (Executive Committee), Purolator Courier Ltd., Tremblant Resort, Cinar Inc., La Laurentienne générale, La Laurentienne vie, Investors Group Inc., Transforce Inc., Intra Continental Insurers Ltd., the National Hockey League Pension Society, Boréal Entreprises Premier CDN Ltée, Les Industries Amisco Ltée, Donohue Matane Inc., La Société de développement du Loisir et du Sport du Québec, the Canadian Olympic Committee, the Canadian Olympic Foundation, member of VANOC's Audit Committee, Governance and Ethics Committee and Observer Team, Sodic Québec Inc., Innovatech Québec, Textile Dionne, Canada's Sports Hall of Fame, the Committee for the 2002 Quebec City Olympic Games Bid, the Committee for the 2015 Toronto Pan American Games Bid, la Fondation Nordiques, etc. He has also presided over the establishment of numerous industrial projects in the greater region of Quebec City.

Michael Cardiff

Mr. Michael A. Cardiff is Independent Director of the Company. He is the Chief Executive Officer of Accelerents, a consulting firm focused on strategy development. Prior to holding that position, Mr. Cardiff held numerous senior positions in a number of technology companies, including large multinationals such as EDS, SAP and IBM, as well as startup companies such as Fincentric, Convergent Technologies, Tandem, and Stratus Computer. Mr. Cardiff is currently a director of Hydrogenics Corporation (NASDAQ: HYGS; TSX: HYG), and Startech.Com Mr. Cardiff has also served as a director of publicly traded companies including Husky Injection Molding, Descartes Systems Group, Visible Genetics and Burntsand Inc. He has also been a director of private companies including Solcorp, Spectra Security Software and Visible Decisions and charitable organizations such as The Toronto Film Festival, Roy Thomson Hall and Medic Alert Foundation. Mr. Cardiff is a member of, and holds the ICD.D designation from, the Institute of Corporate directors.

Jose Dorais

Mr. Jose P. Dorais is Independent Director of AEterna Zentaris Inc. Mr. Dorais is a partner of Miller Thomson LLP, a law firm, where he mainly practices administrative, corporate, business and international trade law. Over his 35-year career, he has worked in both the private and public sectors; in the latter he acted as Secretary to the Minister of Justice and as Secretary of the consulting committee on the Free Trade Agreement for the Quebec Provincial Government. Mr. Dorais has been a member of numerous boards of directors, including the Société des Alcools du Québec, Armand-Frappier Institute, Biochem Pharma and St-Luc Hospital in Montreal. He was, until recently, a member of the Board of Directors of Alliance Films Inc. and Investissement Québec and Chairman of the Board of Foster Wheeler Énergie Inc. He holds a law degree from the University of Ottawa and is a member of the Barreau du Québec.

Juergen Ernst

Mr. Juergen H. L. Ernst is Independent Director of AEterna Zentaris Inc. As the former General Manager of the Pharmaceutical Sector of Solvay S.A. (international chemical and pharmaceutical group), Mr. Ernst has had extensive senior management experience, where, among other functions, he oversaw the human resources department. Mr. Ernst is also a member of the Board of Directors of Pharming Group N.V., a biotechnology company based in the Netherlands.

Gerard Limoges

Mr. Gerard A. Limoges is Independent Director of AEterna Zentaris Inc. Mr. Limoges served as the Deputy Chairman of Ernst & Young LLP Canada until his retirement in September 1999. After a career of 37 years with Ernst & Young, Mr. Limoges has been devoting his time as a director of a number of companies. Mr. Limoges began his career with Ernst & Young in Montreal in 1962. After graduating from the Management Faculty of the Université de Montréal (HEC Montréal) in 1966, he wrote the CICA exams the same year (Honors: Governor General's Gold Medal for the highest marks in Canada and Gold Medal of the Ordre des Comptables Agréés du Québec). He became a chartered accountant in 1967 and partner of Ernst & Young in 1971. After practicing as auditor since 1962 and partner since 1971, he was appointed Managing Partner of the Montreal Office in 1979 and Chairman for Quebec in 1984 when he also joined the National Executive Committee. In 1992, he was appointed Vice Chairman of Ernst & Young Canada and the following year, Deputy Chairman of the Canadian firm. After retirement from practice at the end of September 1999, he was appointed Trustee of the School board of Greater Montreal (1999), member of the Quebec Commission on Health Care and Social Services (2000-2001) and special advisor to the Rector of the Université de Montréal and affiliate schools (2000-2003). Mr. Limoges, at the request of the Board of Directors of the Université de Montréal, participated in the selection of the Dean of the Faculty of Medicine in 2011. Mr. Limoges is also a board member or trustee and chairman of the Audit Committees of the following public companies: Hartco Inc. (TSX) and PROREIT (TSX). He is also a board member of various private companies and charities. Mr. Limoges became an FCPA, FCA (Fellow) in 1984 and received the Order of Canada in 2002. he was appointed Trustee of the School board of Greater Montreal (1999).